Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke

Stroke

Volumn 30, Issue 3, 1999, Pages 508-513

  Albers, Gregory W ^a   Clark, Wayne M ^b   Atkinson, Richard P ^c   Madden, Kenneth ^d   Data, Joann L ^e   Whitehouse, M J ^f  

^a Stanford California and Cofounder   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Mercy General Hospital   (United States)

^d MARSHFIELD CLINIC   (United States)

^e Department of Pharmacokinetics and Drug Metabolism   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cerebral infarction; Neuroprotection; Stroke management; Stroke, acute

Indexed keywords

6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; AGITATION; AMNESIA; ARTICLE; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0032967750     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.3.508     Document Type: Article

References (16)

1. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986;19:105-111.
2. Albers GW, Goldberg MP, Choi DW. N-Methyl-D-aspartate antagonists: ready for clinical trial in brain ischemia? Ann Neurol. 1989;25:398-403.
3. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM, on behalf of the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
4. Dorman PJ, Counsell CE, Sandercrock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs. 1996;5:457-474.
5. Muir DW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
6. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362.
7. Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment: ASSIST Steering Committee. Lancet. 1997;349:32.
8. Carter AJ. Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future. 1992; 17:595-613.
9. Newell DW, Barth A, Malouf AT. Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures. Brain Res. 1995;675:38-44.
10. Yenari MA, Tong DC, Albers GW. Glycine antagonists for treatment of ischemic brain injury in clinical pharmacology of cerebral ischemia. In: Ter Horst GJ, Korf J, eds. Clinical Pharmacology of Cerebral Ischemia. Totowa, NJ: Humana Press Inc; 1996:127-151.
11. The GAIN Investigators. Phase II studies of the glycine antagonist, GV150526, in acute stroke (GAIN). Stroke. 1998;29:304. Abstract.
12. Woodward RM, Huettner JE, Guastella J, Keana FJW, Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995;47:568-581.
13. Myseros J, Oetting GM, Bullock M, Corwin F, Fatouros P. Focal ischemia after therapy with a glutamate antagonist-preserved tissue energy metabolism and reduction in infarct size. J Cereb Blood Flow Metab. 1995;15:S367. Abstract.
14. Warner DS, Martin H, Ludwig P, McAllister A, Keana JFW, Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab. 1995;15:188-196.
15. Xue D, Miyazaki BK, Chen X, Daniell G, Woodward RM. Studies to investigate the minimum effective dose of licostinel (ACEA 1021) in a rat model of transient focal cerebral ischemia. Can J Neurol Sci. 1998; 25(suppl):S13.
16. Whitehouse MJ, Navalta L, Densel M, Ballas M, Davies PJW, Enterling D, Kurth HJ, Weber E. Initial clinical experience with ACEA 1021: safety, tolerance and pharmacokinetics in healthy volunteers. J Stroke Cerebrovasc Dis. 1997;6:151. Abstract.